Ngs-based mutation profiling and pd-l1 expression in nsclc patients: a single-centre prospective analysis

Key Points

• The study aims to evaluate the integration of NGS-based mutation profiling with PD-L1 expression for NSCLC management.
• Prospective analysis conducted at a single center
• NGS-based molecular testing performed
• Assessment of PD-L1 expression across different molecular subtypes
• Lower PD-L1 expression observed in EGFR-mutated tumors
• Higher PD-L1 expression noted in KRAS-mutated tumors
• Distinct patterns of PD-L1 expression emphasize the need for personalized treatment approaches

Abstract